Amgen Inc.

University of California

Jeffrey K Browne

Karen C Sitney

Steven G Elliott

Joan C Egrie

Beverly S Adler

Eryn Ujita-Lee

Karen J Colley

James C Paulson

Jasminder Weinstein

James G Paulson

Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythopoietin analogs, methods of production of the analogs, and compositions comprising the analogs.

Methods and compositions for the prevention and treatment of anemia

Methods for increasing and maintaining hematocrit in a mammal comprising administering a hyperglycosylated analog of erythropoietin are disclosed. An analog may be administered less frequently than an equivalent molar amount of recombinant human erythropoietin to obtain a comparable target hematocrit and treat anemia. Alternatively, a lower molar amount of a hyperglycosylated analog may be administered to obtain a comparable target hematocrit and treat anemia. Also disclosed are new hyperglycosylated erythropoietin analogs, methods of production of the analogs, and compositions comprising the analogs.

A method for genetically engineering cells to produce soluble and secretable Golgi processing enzymes instead of naturally occurring membrane-bound enzymes. Cells are genetically engineered to express glycosyltransferases which lack both a membrane anchor and a retention signal. The resulting altered enzyme becomes soluble and secretable by the cell without losing its catalytic activity. Secretion of the soluble glycosyltransferase by the cell provides for increased production and simplified recovery of glycosyltransferase.

Method for producing secretable glycosyltransferases and other golgi

A microbial shuttle vector is disclosed which is independently replicative in bacterial cells and mammalian cells and includes in its DNA sequence bacterial plasmid sequences allowing selection and replication in bacterial cells, an SV40 viral origin of replication, and either an SV40 functional 'early gene' promoter and functional 'early gene' terminator or an SV40 functional 'late gene' promoter and functional 'late gene' terminator, the vector having a unique restriction endonuclease enzyme recognition site between the promoter and terminator for insertion of an exogenous gene. The presence of restriction endonuclease enzyme recognition sites facilitative of insertion of a viral functional 'late gene' into the 'early gene' promoter/terminator vector in a single step allows for conversion of the shuttle vector into a lytic vector of an exogenous gene. The presence of restriction endonuclease enzyme recognition sites facilitative of insertion of a viral functional 'late gene' into the 'late gene' promoter/terminator vector in a single step allows for conversion of the shuttle vector into a lytic vector.

Papova virus construction

A method for genetically engineering cells to produce soluble and secretable Golgi processing enzymes instead of naturally occurring membrane-bound enzymes. Cells are genetically engineered to express glycosyltransferases which lack both a membrane anchor and a r

Growing community of inventors

Camarillo, CA, United States of America

Jeffrey K Browne